Background. Population-level hepatitis C virus (HCV) infection incidence is a surrogate for community drug-related risk. Methods. We characterized trends in human immunodeficiency virus (HIV) and HCV infection incidence and HCV infection prevalence among injection drug users (IDUs) recruited over
Nearly 30 years into the HIV epidemic, injection drug users (IDUs) remain at high risk for HIV infection. Data from surveillance systems and cohort studies have collectively suggested that HIV infection incidence among IDUs has declined [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] , a trend attributed at least in part to harm-reduction measures including needleexchange programs (NEPs) and substance-abuse treatment. Hepatitis C virus (HCV) is nearly 10 times more transmissible by needlestick than is HIV [12] . Prevalence estimates of HCV infection among IDUs have been reported to exceed 50% in most IDU populations, ranging as high as 95% [13] . Sharing a needle even once is enough to transmit or acquire HCV [14] . Harmreduction measures that have led to declines in HIV infection incidence have not been as successful for HCV infection [15, 16] .
HCV transmission is almost exclusively parenteral, in contrast to the multiple routes of transmission for HIV. Furthermore, drug use is much more likely to result in exposure to HCV than to HIV, and each exposure is more likely to result in transmission, making population-level HCV infection incidence a surrogate for drug-related risk behavior in the community [17, 18] . There are few recent reports on HCV infection incidence among community-based IDUs, but some data suggest that high-risk drug behaviors persist among IDUs. In 2009, the US Centers for Disease Control and Prevention published a report on HIVassociated risk behaviors among 10,000 IDUs sampled from 23 US cities [19] . Overall, one-third of IDUs reported sharing injection equipment in the preceding year and fewer than onethird had participated in an HIV behavioral intervention. Current estimates of HCV infection incidence would provide further context for these reports.
In a community-based cohort of IDUs in Baltimore, Maryland, we previously demonstrated declining HIV infection incidence from 1988 through 2007 [10, 20] . We have also reported on high HCV infection prevalence and incidence among this study's initial cohort, recruited in 1988-1989 [21] . We have recruited additional cohorts of IDUs in more recent periods. The objective of this analysis was to characterize trends in HIV and HCV infection incidence as well as HCV infection prevalence among IDUs over 4 recruitment periods spanning 20 years.
METHODS

Ethics Statement
All participants provided written informed consent, and the study was approved by the Johns Hopkins Bloomberg School of Public Health Institutional Review Board.
Study Population
The AIDS Linked to the Intravenous Experience (ALIVE) study follows a community-based cohort of IDUs in Baltimore that has been described elsewhere [22] . In 1988-1989, 2946 IDUs were enrolled through community outreach and were followed up at 6-month intervals. All participants acknowledged nonmedical injection-drug use within the preceding 11 years, were >18 years of age, and were free of AIDS at entry into the study. In a similar manner, and from the same community, additional persons were recruited into this cohort in 1994-1995 (n 5 391), 1998 (n 5 244), and 2005-2008 (n 5 875). Some recruitment criteria changed over time. In the fourth period, persons were no longer required to be AIDS-free at entry. To replenish with active injectors, in 1994-1995, persons had to have injected in the preceding 3 years, and in 1998 and 2005-2008, in the preceding year.
We calculated HIV infection incidence for each recruitment cohort among persons who were HIV antibody negative at the baseline visit and who had a follow-up visit within 1 year of baseline (n 5 2061). Individuals who were lost-to-follow-up or did not have at least one follow-up visit within 1 year of baseline were excluded. Incidence was calculated to reflect only time until the first follow-up visit that occurred within 1 year of baseline. Incidence was calculated to reflect only time until the first semiannual visit that occurred among this group. HCV infection incidence analysis was performed similarly among those individuals who were HCV antibody negative at the baseline visit and had a follow-up visit within 1 year of baseline (n 5 373).
Individuals were eligible for the HCV infection prevalence analysis only if a serum sample was available for us to test for HCV antibodies at baseline. From the original cohort, we randomly selected 250 persons, 4 of whom had no sample. The random sample was comparable to the full population with respect to demographics and risk behaviors (data not shown 
Measurements
At all study visits, each participant underwent a blood draw and answered a questionnaire that included a combination of interviewer-administered and audio computer-assisted selfinterview (ACASI) questions. Blood samples were stored frozen at 270°C in a repository for future testing. We performed HCV antibody testing on frozen specimens using a second-generation or later enzyme immunoassay (Ortho Diagnostics).
At the baseline visit, we elicited information on demographics, lifetime medical history, and lifetime drug-use and sexual history. Participants were asked about when they started using and injecting drugs; lifetime experience with needle sharing, attending shooting galleries (venues where IDUs can rent, borrow, or purchase injection equipment and where injection equipment is typically used repeatedly), and being in drug treatment of any form, including methadone maintenance and detoxification; and number of sexual partners in the preceding 10 years. At baseline and follow-up visits, we collected data on behaviors in the preceding 6 months, including frequency (categorized as less than daily and at least daily) and types (heroin, cocaine, and speedball) of drugs injected; number of needle-sharing partners (eg, the number of persons with whom needles were shared or number of persons from whom the participant borrowed or rented a needle that had been previously used); shooting-gallery attendance; any drug treatment, specifically methadone maintenance; and number and types of sexual partners. Data on NEP attendance was available only after 1998, so it was not included. Data on sensitive information (eg, drug use) was collected using ACASI after 1998.
Statistical Analysis
We compared characteristics of participants across the 4 recruitment periods using v 2 tests for categorical variables and the Kruskal-Wallis test for continuous variables. We calculated incidence as the number of new HIV or HCV infections divided by person-years (py) of follow-up between baseline and the first semi-annual follow-up visit (as long as the visit was within 1 year of baseline) for persons initially HIV or HCV antibody negative. We did not perform multivariate analysis for HIV because we observed no infections in either the 1998 or 2005-2008 cohorts. We used Poisson regression to calculate incidence-rate ratios of HCV infection by recruitment cohort after adjustment. We built models sequentially to assess the impact of different factors. Initially, we included differences across recruitment cohorts to ensure that the differences observed were not explained by changes in the populations over time. First, we included only age and time since first injection followed by demographic variables (sex, race, and educational attainment) and HIV serostatus. We constructed subsequent models to determine whether any of the changes observed were explained by changes in recent drug-use or sexual risk behaviors over time. Drug-related risk behaviors included frequency of injection, needle sharing, shooting gallery attendance, and drug treatment in the preceding 6 months; sexual risk behaviors included number of sexual partners and self-reported sexually transmitted infections in the preceding 6 months. We also constructed models varying the order in which variables were included (eg, drug behaviors before demographics). We compared HCV infection prevalence across the 4 cohorts using the v 2 test for trend. We used Poisson regression with robust variance estimation to calculate prevalence ratios of HCV infection by recruitment cohort after adjusting for differences in confounders across recruitment cohorts and the impact of changes in risk behavior. The model-building strategy was similar to that described for HCV infection incidence. The primary difference was that in the prevalence models, we included lifetime risk behaviors rather than recent risk behaviors. We assessed effect modification by age and years since first reported injection on the association between recruitment cohort and HCV infection prevalence by including interaction terms in regression models. All statistical analyses were performed using Stata software (version 10.1; StataCorp). Table 1 illustrates characteristics of the 4 recruitment cohorts at enrollment. Over time, the cohorts were older and the median duration of injection drug use was longer. Compared with the 1988-1989 cohort, subsequent recruitments included more women. The first 3 cohorts had a higher proportion of African Americans compared with the most recent recruitment (P , .001 for all). There were no statistically significant differences in marital status or educational attainment over time. The 2 later cohorts had a higher proportion of individuals with no formal income. HIV infection prevalence fluctuated from 23% in 1988-89 to 11 % in 1994-95 to 31% in 1998 and 23% in 2005-08. There were some variations in injection practices over time, some of which reflect recruitment differences. The proportion of participants who reported ever sharing needles over time decreased slightly; however, the proportion who reported ever attending a shooting gallery increased, as did the proportion who reported ever being in drug treatment (P , .001). ). These differences strengthened in magnitude after adjustment for demographics, duration of injection, and HIV serostatus; however, none were statistically significant ( Table 2 , models 2 and 3). Neither drug-related nor sexual-related risk behavior explained a large proportion of the change in HCV infection incidence over time (Table 2 , models 4 and 5). For example, the IRR before adjusting for drug-related risk behavior was .38 (95% CI, .09-1.62), whereas after adjusting for drug-related risk behavior the IRR was .43 (95% CI, .09-2.18).
RESULTS
Trends in Hepatitis C Virus Infection Prevalence
We observed similar trends in the association between recruitment cohort and HCV infection prevalence across strata of age and years since first injection. A statistically significant decline in HCV infection prevalence was observed among persons who were younger (,39 years of age) and had shorter injection history (,15 years) but not among those who were older and injecting for longer. Figure 2 shows HCV infection prevalence by age. Because differences across cohorts over time were heterogeneous across strata of age, all analyses included an interaction between age (stratified at the median of 39 years) and recruitment cohort. The pattern of decline in HCV infection prevalence over time among individuals aged ,39 years persisted after adjustment for demographic factors and injection duration differences across recruitment cohorts ( Figure 3A) . All cohorts exhibited statistically significant differences in HCV infection prevalence relative to the 1988-1989 cohort (model 2); there was also a decline between the 1998 and 1994-1995 cohorts (PR, .82; 95% CI, .69-.97; P 5 .02) and a statistically nonsignificant increase between the 1998 and 2005-2008 cohorts (PR, 1.08; 95% CI, .91-1.29; P 5 .38). These changes were not largely explained by differences in lifetime drug-related or sexual-related risk behavior across the cohorts, as adjustment for these behaviors did not substantially attenuate the PRs (model 3).
Among individuals aged >39 years, after adjustment for demographic and time since injection differences, there were no statistically significant differences between the 1994-1995 or the 
DISCUSSION
In this cohort of IDUs, we observed a dramatic decline in HIV infection incidence over 2 decades; no new infections occurred within the first year of follow-up in cohorts recruited in 1998 forward. Reductions in HCV infection incidence and prevalence were also observed over the same period, most notably among persons who had started injection recently and were younger. However, similar prevalences of HCV infection over time among those who were injecting longer and were older suggest that these improvements delay but do not prevent HCV infection at the population level. Collectively, these data support intensifying the harm-reduction strategies that have markedly reduced HIV transmission to reduce further the risk of HCV infection. Large-scale expansion of NEPs and opiate substitution treatment programs appear to have reduced HIV transmission among IDUs [6, 7, 23] . Accordingly, in this Baltimore IDU cohort, we have seen marked reductions in HIV infection incidence over 2 decades [10, 20] . In this analysis, we also detected a decline in HCV infection incidence as well as HCV infection prevalence among those who were younger or had recently started injection. Importantly, we observed that HCV acquisition may be delayed by up to 10 years among IDUs compared with that in the late 1980s when the epidemic was at peak. These results are consistent with a recent meta-analysis by Hagan and colleagues [24] that suggested that time to HCV infection has lengthened in developed countries as well as a number of reports suggesting declines among younger injectors and new initiates [25] [26] [27] [28] [29] [30] . Although we hypothesize that these declines are due to expanded harm-reduction efforts and reduction in drug-related risk behavior, our data did not demonstrate that changes in self-reported injection behavior had substantial impact. Of note, we were not able to account for changes in NEP attendance.
Despite reductions in HCV infection prevalence among younger individuals, we did not observe declines in HCV burden in those who were older and had longer injection histories, with the exception of a slight reduction among the most recent cohort compared with the earliest. It is possible that we failed to observe a difference over time among older IDUs with longer history of injection because it will simply take longer for reductions in HCV infection incidence to impact prevalence among older individuals, given that many of the individuals in this older age group were likely infected 20-25 years ago, prior to expanded harm-reduction strategies. This hypothesis is supported by the significantly lower prevalence among older IDUs in the most recent recruitment cohort.
However, it is important to consider other reasons why analogous reductions in HCV infection among older persons with a history of drug injection have not been detected. HCV is an order of magnitude more transmissible than HIV by a single needlestick [12] . Thus, measures that reduce the likelihood of viral exposure or that reduce the number of viruses in each exposure might be sufficient to affect HIV infection incidence without having a commensurate effect on HCV infection. Interventions such as NEPs and opiate substitution may reach IDUs too late in their injecting careers to have a significant impact on HCV infection incidence. Furthermore, although these measures may reduce the frequency of needle sharing that may be sufficient to impact HIV transmission, they may not completely eliminate risk behavior, making them insufficient to effectively prevent HCV transmission throughout an IDU's injection career.
Data from this cohort and many others indicate the risk of HCV-related liver disease sharply rises in persons aged .40 years [31] [32] [33] . It is difficult to disentangle the effects of age and duration of HCV infection on disease progression, and despite some public health benefits of delaying HCV infection, it will likely not be sufficient to prevent the long-term complications of disease in a large proportion of IDUs. Even with some reduction in transmission, of the 2005-2008 cohort, .80% of individuals >39 years old are infected with HCV and at risk for developing any of the complications associated with chronic liver disease. Furthermore, this level of prevalence points to a large reservoir of HCV infection among this population, which significantly hampers prevention efforts.
Efforts need to be intensified on both the prevention and treatment fronts to reduce the reservoir of HCV-infected IDUs. For many persons, the interval between initiation and injection simply remains too brief for prevention strategies to be successful. Targeting very young IDUs or drug users who have not yet transitioned to injection is critical. However, because transmission continues to occur even among older IDUs, prevention strategies must target IDUs at all stages and ages, and it may be that different strategies are needed for different subpopulations. The other method for reducing the size of the reservoir is HCV infection treatment. Current treatment regimens have limited efficacy among certain subpopulations. In particular, our population in Baltimore is predominantly infected with genotype 1 and African American, with a high prevalence of HIV co-infection, all of which are factors associated with reduced treatment success [34] [35] [36] . The impact of treatment in reducing HCV burden is likely to have been minimal, because we and others have demonstrated that few IDUs are engaged in care for HCV infection and even fewer successfully clear their HCV infections [40] . With new, more efficacious therapeutics on the horizon [41] , it is critical that strategies to improve uptake and completion of HCV infection treatment of IDUs be implemented, because treatment is the only option for the large numbers of IDUs already infected with HCV.
We were limited in this analysis by not having HCV testing on the full baseline recruitment cohort; however, the random sample did appear to be similar to the full baseline cohort with respect to key covariates that would be associated with HCV infection prevalence. Our analysis was further limited by the small number of persons who were HCV antibody negative at baseline; this is a common problem in epidemiologic studies among IDUs. All of our behavioral data were collected via selfreport, a method that has inherent limitations, some of which may have impaired our ability to assess how much impact behavior change had, particularly in the analysis of HCV infection prevalence. We cannot rule out the possibility of variability in unmeasured individual factors or secular changes across the cohorts that could have impacted prevalence and incidence. Eligibility criteria slightly changed over time, and we observed that a number of factors, including HIV serostatus, differed across recruitment cohorts. Although we adjusted for all measured confounders, we cannot rule out the possibility of residual confounding. Finally, prevalence estimates are impacted by both incidence and mortality, and it is possible that some of the early changes in prevalence observed actually reflect the high levels of mortality due to drug overdose and AIDS in the era prior to the use of highly active antiretroviral therapy (HAART). However, continued declines even after 1996 suggest that some of this difference may be because of reduced incidence as well. Finally, behavioral data were collected by interviewer-administered questionnaire prior to 1998 and via ACASI after 1998, which may have further impacted differences.
These limitations notwithstanding, the data collectively suggest that harm-reduction strategies that have been successful for HIV infection may also be contributing to declines in HCV acquisition. However, additional, more intensive strategies, particularly those that target new initiates into drug injection, are needed to significantly impact community-level drug-related risk. Furthermore, HCV infection prevalence and incidence remain up to 10-fold higher than those of HIV infection in this population, reinforcing not only the continued need for preventive measures but also the need to expand care and treatment to those already infected.
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